These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 16957636)

  • 1. When is critical care medicine cost-effective? A systematic review of the cost-effectiveness literature.
    Talmor D; Shapiro N; Greenberg D; Stone PW; Neumann PJ
    Crit Care Med; 2006 Nov; 34(11):2738-47. PubMed ID: 16957636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Understanding costs and cost-effectiveness in critical care: report from the second American Thoracic Society workshop on outcomes research.
    Am J Respir Crit Care Med; 2002 Feb; 165(4):540-50. PubMed ID: 11850349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Effectiveness Studies in the ICU: A Systematic Review.
    Wilcox ME; Vaughan K; Chong CAKY; Neumann PJ; Bell CM
    Crit Care Med; 2019 Aug; 47(8):1011-1017. PubMed ID: 30985446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An overview of economic evaluations for drugs used in rheumatoid arthritis : focus on tumour necrosis factor-alpha antagonists.
    Bansback NJ; Regier DA; Ara R; Brennan A; Shojania K; Esdaile JM; Anis AH; Marra CA
    Drugs; 2005; 65(4):473-96. PubMed ID: 15733011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Approach to economic analysis in critical care.
    Kyeremanteng K; Wan C; D'Egidio G; Neilipovitz D
    J Crit Care; 2016 Dec; 36():92-96. PubMed ID: 27546754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of recombinant human erythropoietin for reducing red blood cells transfusions in critically ill patients.
    MacLaren R; Sullivan PW
    Value Health; 2005; 8(2):105-16. PubMed ID: 15804319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-Effectiveness of Treatment Options for Neuropathic Pain: a Systematic Review.
    Ruiz-Negrón N; Menon J; King JB; Ma J; Bellows BK
    Pharmacoeconomics; 2019 May; 37(5):669-688. PubMed ID: 30637713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of a multifaceted intervention QI program to improve ICU performance.
    Ersson A; Beckman A; Jarl J; Borell J
    BMC Health Serv Res; 2018 Nov; 18(1):838. PubMed ID: 30404646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost effectiveness of adult intensive care in the UK.
    Ridley S; Morris S
    Anaesthesia; 2007 Jun; 62(6):547-54. PubMed ID: 17506731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analyses in orthopaedic sports medicine: a systematic review.
    Nwachukwu BU; Schairer WW; Bernstein JL; Dodwell ER; Marx RG; Allen AA
    Am J Sports Med; 2015 Jun; 43(6):1530-7. PubMed ID: 25125693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Volume and health outcomes: evidence from systematic reviews and from evaluation of Italian hospital data.
    Amato L; Fusco D; Acampora A; Bontempi K; Rosa AC; Colais P; Cruciani F; D'Ovidio M; Mataloni F; Minozzi S; Mitrova Z; Pinnarelli L; Saulle R; Soldati S; Sorge C; Vecchi S; Ventura M; Davoli M
    Epidemiol Prev; 2017; 41(5-6 (Suppl 2)):1-128. PubMed ID: 29205995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economics of end-of-life care in the intensive care unit.
    Pronovost P; Angus DC
    Crit Care Med; 2001 Feb; 29(2 Suppl):N46-51. PubMed ID: 11228573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intensive care, survival, and expense of treating critically ill cancer patients.
    Schapira DV; Studnicki J; Bradham DD; Wolff P; Jarrett A
    JAMA; 1993 Feb; 269(6):783-6. PubMed ID: 8423662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes and cost-effectiveness of initiating dialysis and continuing aggressive care in seriously ill hospitalized adults. SUPPORT Investigators. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments.
    Hamel MB; Phillips RS; Davis RB; Desbiens N; Connors AF; Teno JM; Wenger N; Lynn J; Wu AW; Fulkerson W; Tsevat J
    Ann Intern Med; 1997 Aug; 127(3):195-202. PubMed ID: 9245224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simplified pharmacoeconomics of critical care and severe sepsis.
    Ernst FR; Levy H; Qualy RL
    J Intensive Care Med; 2007; 22(5):283-93. PubMed ID: 17895486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.
    McKenna C; Burch J; Suekarran S; Walker S; Bakhai A; Witte K; Harden M; Wright K; Woolacott N; Lorgelly P; Fenwick L; Palmer S
    Health Technol Assess; 2010 May; 14(24):1-162. PubMed ID: 20492762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-utility analysis studies of depression management: a systematic review.
    Pirraglia PA; Rosen AB; Hermann RC; Olchanski NV; Neumann P
    Am J Psychiatry; 2004 Dec; 161(12):2155-62. PubMed ID: 15569883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of drotrecogin alfa (activated).
    Tsitanidis J
    Crit Care Med; 2003 Sep; 31(9):2414-5; author reply 2415. PubMed ID: 14501983
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.